Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was r...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2019/9026121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560381658136576 |
|---|---|
| author | S. Nguyen P. Teh J. Zhou E. Y. Chang A. von Drygalski |
| author_facet | S. Nguyen P. Teh J. Zhou E. Y. Chang A. von Drygalski |
| author_sort | S. Nguyen |
| collection | DOAJ |
| description | Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was recently approved for rescue treatment but with little evidence-based information regarding efficacy. We report a case of papillary thyroid cancer associated with AHA malignancy that responded to a single dose of rpFVIII after failure to achieve hemostasis with FVIIa-based bypassing products. |
| format | Article |
| id | doaj-art-53879028ec4c40db86f50d1507fdc06c |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-53879028ec4c40db86f50d1507fdc06c2025-02-03T01:27:39ZengWileyCase Reports in Hematology2090-65602090-65792019-01-01201910.1155/2019/90261219026121Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIIIS. Nguyen0P. Teh1J. Zhou2E. Y. Chang3A. von Drygalski4Department of Medicine, University of California San Diego, San Diego, CA, USADepartment of Medicine, University of California Riverside, Riverside, CA, USADepartment of Medicine, University of California San Diego, San Diego, CA, USARadiology Service, VA San Diego Healthcare System, San Diego, CA, USADepartment of Medicine, University of California San Diego, San Diego, CA, USAAcquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies against Factor VIII (FVIII). It has a high mortality due to bleeding complications. FVIIa-based bypassing agents are the first line of treatment but not always effective. Recombinant porcine (rp) FVIII (Obizur®) was recently approved for rescue treatment but with little evidence-based information regarding efficacy. We report a case of papillary thyroid cancer associated with AHA malignancy that responded to a single dose of rpFVIII after failure to achieve hemostasis with FVIIa-based bypassing products.http://dx.doi.org/10.1155/2019/9026121 |
| spellingShingle | S. Nguyen P. Teh J. Zhou E. Y. Chang A. von Drygalski Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII Case Reports in Hematology |
| title | Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII |
| title_full | Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII |
| title_fullStr | Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII |
| title_full_unstemmed | Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII |
| title_short | Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII |
| title_sort | acquired hemophilia a fviii deficiency associated with papillary thyroid cancer treatment with recombinant porcine fviii |
| url | http://dx.doi.org/10.1155/2019/9026121 |
| work_keys_str_mv | AT snguyen acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii AT pteh acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii AT jzhou acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii AT eychang acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii AT avondrygalski acquiredhemophiliaafviiideficiencyassociatedwithpapillarythyroidcancertreatmentwithrecombinantporcinefviii |